首页 > 最新文献

Respiratory Medicine and Research最新文献

英文 中文
Sarcoid-like reaction related to ALK-ROS inhibitors in lung cancer patients 肺癌患者与 ALK-ROS 抑制剂有关的肉样瘤样反应
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-30 DOI: 10.1016/j.resmer.2024.101138
Clara Morin , Thomas Villeneuve, Emma Norkowski, Lise Rosencher, Jacques Cadranel, Julien Mazières
{"title":"Sarcoid-like reaction related to ALK-ROS inhibitors in lung cancer patients","authors":"Clara Morin , Thomas Villeneuve, Emma Norkowski, Lise Rosencher, Jacques Cadranel, Julien Mazières","doi":"10.1016/j.resmer.2024.101138","DOIUrl":"10.1016/j.resmer.2024.101138","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101138"},"PeriodicalIF":2.2,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142238594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidental pulmonary nodules: Natural language processing analysis of radiology reports 偶然发现的肺结节放射学报告的自然语言处理分析
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-22 DOI: 10.1016/j.resmer.2024.101136
Emmanuel Grolleau , Sébastien Couraud , Emilien Jupin Delevaux , Céline Piegay , Adeline Mansuy , Julie de Bermont , François Cotton , Jean-Baptiste Pialat , François Talbot , Loïc Boussel

Background

Pulmonary nodules are a common incidental finding on chest Computed Tomography scans (CT), most of the time outside of lung cancer screening (LCS). We aimed to evaluate the number of incidental pulmonary nodules (IPN) found in 1 year in our hospital, as well as the follow-up (FUP) rate and the clinical and radiological features associated with FUP.

Methods

We trained a Natural Language Processing (NLP) tool to identify the transcripts mentioning the presence of a pulmonary nodule, among a large population of patients from a French hospital. We extracted nodule characteristics using keyword analysis. NLP algorithm accuracy was determined through manual reading from a sample of our population. Electronic health database and medical record analysis by clinician allowed us to obtain information about FUP and cancer diagnoses.

Results

In this retrospective observational study, we analyzed 101,703 transcripts corresponding to the entire CTs performed in 2020. We identified 1,991 (2 %) patients with an IPN. NLP accuracy for nodule detection in CT reports was 99 %. Only 41 % received a FUP between January 2020 and December 2021. Patient age, nodule size, and the mention of the nodule in the impression part were positively associated with FUP, while nodules diagnosed in the context of COVID-19 were less followed. 36 (2 %) lung cancers were subsequently diagnosed, with 16 (45 %) at a non-metastatic stage.

Conclusions

We identified a high prevalence of IPN with a low FUP rate, encouraging the implementation of IPN management program. We also highlighted the potential of NLP for database analysis in clinical research.

背景肺结节是胸部计算机断层扫描(CT)中常见的偶然发现,多数情况下不属于肺癌筛查(LCS)范围。我们的目的是评估我们医院一年内发现的偶然肺结节(IPN)的数量、随访率(FUP)以及与 FUP 相关的临床和放射学特征。我们通过关键词分析提取了结节的特征。NLP 算法的准确性是通过人工阅读人群样本确定的。通过临床医生的电子健康数据库和病历分析,我们获得了有关肺结核和癌症诊断的信息。结果在这项回顾性观察研究中,我们分析了与 2020 年进行的全部 CT 相对应的 101,703 份记录誊本。我们发现了 1,991 例(2%)IPN 患者。CT 报告中结节检测的 NLP 准确率为 99%。在 2020 年 1 月至 2021 年 12 月期间,只有 41% 的患者接受了 FUP。患者年龄、结节大小以及在印象部分提及结节与FUP呈正相关,而在COVID-19背景下诊断出的结节则较少被关注。结论我们发现 IPN 的发病率很高,而 FUP 率却很低,因此鼓励实施 IPN 管理计划。我们还强调了 NLP 在临床研究数据库分析方面的潜力。
{"title":"Incidental pulmonary nodules: Natural language processing analysis of radiology reports","authors":"Emmanuel Grolleau ,&nbsp;Sébastien Couraud ,&nbsp;Emilien Jupin Delevaux ,&nbsp;Céline Piegay ,&nbsp;Adeline Mansuy ,&nbsp;Julie de Bermont ,&nbsp;François Cotton ,&nbsp;Jean-Baptiste Pialat ,&nbsp;François Talbot ,&nbsp;Loïc Boussel","doi":"10.1016/j.resmer.2024.101136","DOIUrl":"10.1016/j.resmer.2024.101136","url":null,"abstract":"<div><h3>Background</h3><p>Pulmonary nodules are a common incidental finding on chest Computed Tomography scans (CT), most of the time outside of lung cancer screening (LCS). We aimed to evaluate the number of incidental pulmonary nodules (IPN) found in 1 year in our hospital, as well as the follow-up (FUP) rate and the clinical and radiological features associated with FUP.</p></div><div><h3>Methods</h3><p>We trained a Natural Language Processing (NLP) tool to identify the transcripts mentioning the presence of a pulmonary nodule, among a large population of patients from a French hospital. We extracted nodule characteristics using keyword analysis. NLP algorithm accuracy was determined through manual reading from a sample of our population. Electronic health database and medical record analysis by clinician allowed us to obtain information about FUP and cancer diagnoses.</p></div><div><h3>Results</h3><p>In this retrospective observational study, we analyzed 101,703 transcripts corresponding to the entire CTs performed in 2020. We identified 1,991 (2 %) patients with an IPN. NLP accuracy for nodule detection in CT reports was 99 %. Only 41 % received a FUP between January 2020 and December 2021. Patient age, nodule size, and the mention of the nodule in the impression part were positively associated with FUP, while nodules diagnosed in the context of COVID-19 were less followed. 36 (2 %) lung cancers were subsequently diagnosed, with 16 (45 %) at a non-metastatic stage.</p></div><div><h3>Conclusions</h3><p>We identified a high prevalence of IPN with a low FUP rate, encouraging the implementation of IPN management program. We also highlighted the potential of NLP for database analysis in clinical research.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101136"},"PeriodicalIF":2.2,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000527/pdfft?md5=db4810650b3b1f71ba6bb1bfcd967a3b&pid=1-s2.0-S2590041224000527-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142130146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescents with cystic fibrosis 评估囊性纤维化成人和青少年的 EQ-5D-5L 与疾病严重程度和生活质量之间的对应关系
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-20 DOI: 10.1016/j.resmer.2024.101137
Rana Altabee , Siobhan B. Carr , Janice Abbott , Rory Cameron , Daniel Office , Nicholas J. Simmonds , Jennifer A. Whitty , David Turner , Garry Barton

Background

The EQ-5D is the recommended measure to capture health-related quality of life (HRQoL), recognised for use in health technology appraisal bodies. In order to assess whether it is appropriate to use the EQ-5D for making decisions about the cost-utility of treatments in cystic fibrosis (CF), this study assesses the performance of the EQ-5D-5L in adults and adolescents with CF.

Method

This was a cross-sectional observational survey study of patients with CF attending a single large CF centre. Participants were asked to complete a survey that included two HRQoL measures; the EQ-5D-5L and CF Quality of Life (CFQoL) questionnaires.

Results

Among 213 participants, the median EQ-5D-5L index score was 0.76 (IQR 0.66 – 0.84) and the visual analogue (EQ-VAS) was 70 (60 – 80). Both the EQ-5D index and EQ-VAS discriminated between disease severity based on lung function (p = 0.01 and p < 0.01, respectively) and pulmonary exacerbation (p = 0.02 and p < 0.01, respectively); however, EQ-VAS differentiated between more lung function severity groups compared to EQ-5D index. The EQ-5D-5L demonstrated convergent validity as its dimensions, index score, and EQ-VAS had significant correlations with most CFQoL domains. Though, EQ-VAS significantly predicted more domains of CFQoL (4 domains) compared to EQ-5D index (only 1 domain).

Conclusion

The generic EQ-5D-5L performed adequately in discriminating between CF disease severity, and its index score and EQ-VAS had moderate correlations with CFQoL. However, using a complementary condition-specific measure alongside the EQ-5D-5L can provide better insight of HRQoL in CF and benefit the process of cost-utility analysis.

背景EQ-5D是衡量健康相关生活质量(HRQoL)的推荐指标,被卫生技术评估机构认可使用。为了评估在囊性纤维化(CF)治疗的成本效用决策中使用 EQ-5D 是否合适,本研究评估了 EQ-5D-5L 在成人和青少年 CF 患者中的表现。结果在213名参与者中,EQ-5D-5L指数的中位数为0.76(IQR为0.66 - 0.84),视觉模拟(EQ-VAS)为70(60 - 80)。EQ-5D 指数和 EQ-VAS 都能根据肺功能(分别为 p = 0.01 和 p < 0.01)和肺部恶化(分别为 p = 0.02 和 p < 0.01)区分疾病严重程度;然而,与 EQ-5D 指数相比,EQ-VAS 能区分更多的肺功能严重程度组别。由于 EQ-5D-5L 的维度、指数得分和 EQ-VAS 与大多数 CFQoL 领域都有显著相关性,因此 EQ-5D-5L 显示出了收敛有效性。结论 通用的 EQ-5D-5L 在区分 CF 疾病严重程度方面表现出色,其指数得分和 EQ-VAS 与 CFQoL 具有适度的相关性。然而,在使用EQ-5D-5L的同时,使用针对特定疾病的补充测量方法可以更好地了解CF的HRQoL,并有利于成本效用分析过程。
{"title":"Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescents with cystic fibrosis","authors":"Rana Altabee ,&nbsp;Siobhan B. Carr ,&nbsp;Janice Abbott ,&nbsp;Rory Cameron ,&nbsp;Daniel Office ,&nbsp;Nicholas J. Simmonds ,&nbsp;Jennifer A. Whitty ,&nbsp;David Turner ,&nbsp;Garry Barton","doi":"10.1016/j.resmer.2024.101137","DOIUrl":"10.1016/j.resmer.2024.101137","url":null,"abstract":"<div><h3>Background</h3><p>The EQ-5D is the recommended measure to capture health-related quality of life (HRQoL), recognised for use in health technology appraisal bodies. In order to assess whether it is appropriate to use the EQ-5D for making decisions about the cost-utility of treatments in cystic fibrosis (CF), this study assesses the performance of the EQ-5D-5L in adults and adolescents with CF.</p></div><div><h3>Method</h3><p>This was a cross-sectional observational survey study of patients with CF attending a single large CF centre. Participants were asked to complete a survey that included two HRQoL measures; the EQ-5D-5L and CF Quality of Life (CFQoL) questionnaires.</p></div><div><h3>Results</h3><p>Among 213 participants, the median EQ-5D-5L index score was 0.76 (IQR 0.66 – 0.84) and the visual analogue (EQ-VAS) was 70 (60 – 80). Both the EQ-5D index and EQ-VAS discriminated between disease severity based on lung function (<em>p</em> = 0.01 and <em>p</em> &lt; 0.01, respectively) and pulmonary exacerbation (<em>p</em> = 0.02 and <em>p</em> &lt; 0.01, respectively); however, EQ-VAS differentiated between more lung function severity groups compared to EQ-5D index. The EQ-5D-5L demonstrated convergent validity as its dimensions, index score, and EQ-VAS had significant correlations with most CFQoL domains. Though, EQ-VAS significantly predicted more domains of CFQoL (4 domains) compared to EQ-5D index (only 1 domain).</p></div><div><h3>Conclusion</h3><p>The generic EQ-5D-5L performed adequately in discriminating between CF disease severity, and its index score and EQ-VAS had moderate correlations with CFQoL. However, using a complementary condition-specific measure alongside the EQ-5D-5L can provide better insight of HRQoL in CF and benefit the process of cost-utility analysis.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101137"},"PeriodicalIF":2.2,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000539/pdfft?md5=b71da58ca67010b88f93e6e2d262327d&pid=1-s2.0-S2590041224000539-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Description, clinical impact and early outcome of S. maltophilia respiratory tract infections after lung transplantation, A retrospective observational study 肺移植术后嗜麦芽汁酵母菌呼吸道感染的描述、临床影响和早期预后:一项回顾性观察研究
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-19 DOI: 10.1016/j.resmer.2024.101130
Benoît Pilmis , Claire Rouzaud , Deborah To-Puzenat , Anne Gigandon , Gaelle Dauriat , Séverine Feuillet , Delphine Mitilian , Justin Issard , Alban Le Monnier , Olivier Lortholary , Elie Fadel , Jérôme Le Pavec

Background and research question

S. maltophilia infections are associated with significant morbidity and mortality. Little is known regarding its presentation, management, and outcome in lung transplant recipients.

Study design and Methods

This retrospective case control study reviewed S. maltophilia respiratory tract infection in lung transplant recipients (01/01/2011-31/01/2020) and described the clinical, microbiological and outcome characteristics matched with lung transplant recipients without respiratory tract infection.

Results and interpretation

We identified 63 S. maltophilia infections in lung transplant recipients. Among them none were colonized before transplantation. Infections occurred a median of 177 (IQR: 45- 681) days post transplantation. Fifty-four (85.7 %) patients received trimethoprim-sulfamethoxazole (400/80 mg three times a week) to prevent Pneumocystis jirovecii pneumonia (PJP). S. maltophilia strains were susceptible to trimethoprim-sulfamethoxazole, levofloxacin, minocycline and ceftazidime in respectively 85.7 %, 82.5 %, 96.8 % and 34.9 % of cases. Median duration of treatment was 9 days (IQR 7–11.5). Clinical and microbiological recurrence were observed in respectively 25.3 % and 39.7 % of cases. Combination therapy was not associated with a decrease in the risk of recurrence and did not prevent the emergence of resistance. S. maltophilia respiratory tract infection was associated with a decline in FEV-1 at one year.

Conclusion

S. maltophilia is an important cause of lower respiratory tract infection in lung transplant recipients. Trimethoprim-sulfamethoxazole use as prophylaxis for PJP doesn't prevent S. maltophilia infection among lung transplant recipients. Levofloxacin and trimethoprim-sulfamethoxazole appear to be the two molecules of choice for the treatment of these infections and new antibiotic strategies (cefiderocol, aztreonam/avibactam) are currently being evaluated for multi-resistant S. maltophilia infections.

背景和研究问题嗜麦芽糖浆菌感染与严重的发病率和死亡率有关。这项回顾性病例对照研究回顾了肺移植受者(01/01/2011-31/01/2020)中嗜麦芽梭菌呼吸道感染的情况,并描述了与无呼吸道感染的肺移植受者相匹配的临床、微生物学和结果特征。其中没有人在移植前就已感染。感染发生的时间中位数为移植后 177 天(IQR:45- 681 天)。54名患者(85.7%)接受了三甲双胍-磺胺甲噁唑治疗(400/80 毫克,每周三次),以预防肺孢子虫肺炎(PJP)。分别有 85.7%、82.5%、96.8% 和 34.9% 的病例中,嗜麦芽糖球菌菌株对三甲双胍-磺胺甲恶唑、左氧氟沙星、米诺环素和头孢他啶敏感。中位治疗时间为 9 天(IQR 7-11.5)。临床和微生物复发率分别为 25.3% 和 39.7%。联合疗法并不能降低复发风险,也不能防止耐药性的产生。结论嗜麦芽梭菌是肺移植受者下呼吸道感染的一个重要原因。使用三甲氧苄啶-磺胺甲噁唑预防 PJP 并不能预防肺移植受者感染嗜麦芽梭菌。左氧氟沙星和三甲氧苄氨嘧啶-磺胺甲噁唑似乎是治疗这些感染的首选药物,目前正在对治疗嗜麦芽糖酵母菌多重耐药性感染的新抗生素策略(头孢羟氨苄、阿曲南/阿维巴坦)进行评估。
{"title":"Description, clinical impact and early outcome of S. maltophilia respiratory tract infections after lung transplantation, A retrospective observational study","authors":"Benoît Pilmis ,&nbsp;Claire Rouzaud ,&nbsp;Deborah To-Puzenat ,&nbsp;Anne Gigandon ,&nbsp;Gaelle Dauriat ,&nbsp;Séverine Feuillet ,&nbsp;Delphine Mitilian ,&nbsp;Justin Issard ,&nbsp;Alban Le Monnier ,&nbsp;Olivier Lortholary ,&nbsp;Elie Fadel ,&nbsp;Jérôme Le Pavec","doi":"10.1016/j.resmer.2024.101130","DOIUrl":"10.1016/j.resmer.2024.101130","url":null,"abstract":"<div><h3>Background and research question</h3><p><em>S. maltophilia</em> infections are associated with significant morbidity and mortality. Little is known regarding its presentation, management, and outcome in lung transplant recipients.</p></div><div><h3>Study design and Methods</h3><p>This retrospective case control study reviewed <em>S. maltophilia</em> respiratory tract infection in lung transplant recipients (01/01/2011-31/01/2020) and described the clinical, microbiological and outcome characteristics matched with lung transplant recipients without respiratory tract infection.</p></div><div><h3>Results and interpretation</h3><p>We identified 63 <em>S. maltophilia</em> infections in lung transplant recipients. Among them none were colonized before transplantation. Infections occurred a median of 177 (IQR: 45- 681) days post transplantation. Fifty-four (85.7 %) patients received trimethoprim-sulfamethoxazole (400/80 mg three times a week) to prevent <em>Pneumocystis jirovecii</em> pneumonia (PJP). <em>S. maltophilia</em> strains were susceptible to trimethoprim-sulfamethoxazole, levofloxacin, minocycline and ceftazidime in respectively 85.7 %, 82.5 %, 96.8 % and 34.9 % of cases. Median duration of treatment was 9 days (IQR 7–11.5). Clinical and microbiological recurrence were observed in respectively 25.3 % and 39.7 % of cases. Combination therapy was not associated with a decrease in the risk of recurrence and did not prevent the emergence of resistance. <em>S. maltophilia</em> respiratory tract infection was associated with a decline in FEV-1 at one year.</p></div><div><h3>Conclusion</h3><p><em>S. maltophilia</em> is an important cause of lower respiratory tract infection in lung transplant recipients. Trimethoprim-sulfamethoxazole use as prophylaxis for PJP doesn't prevent <em>S. maltophilia</em> infection among lung transplant recipients. Levofloxacin and trimethoprim-sulfamethoxazole appear to be the two molecules of choice for the treatment of these infections and new antibiotic strategies (cefiderocol, aztreonam/avibactam) are currently being evaluated for multi-resistant <em>S. maltophilia</em> infections.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101130"},"PeriodicalIF":2.2,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142162991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Massive hemoptysis: A normal platelet count may not be enough 大咯血:正常的血小板计数可能不够
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-08 DOI: 10.1016/j.resmer.2024.101134
Thibaud Soumagne, Dominique Helley, Sébastien Eymieux, Laurent Frenzel, Anne Vincenot, Alessandro Di Gaeta, Olivier Pellerin, Benjamin Planquette, Nicolas Gendron
{"title":"Massive hemoptysis: A normal platelet count may not be enough","authors":"Thibaud Soumagne,&nbsp;Dominique Helley,&nbsp;Sébastien Eymieux,&nbsp;Laurent Frenzel,&nbsp;Anne Vincenot,&nbsp;Alessandro Di Gaeta,&nbsp;Olivier Pellerin,&nbsp;Benjamin Planquette,&nbsp;Nicolas Gendron","doi":"10.1016/j.resmer.2024.101134","DOIUrl":"10.1016/j.resmer.2024.101134","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101134"},"PeriodicalIF":2.2,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142097723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetes mellitus with poor glycemic control is a risk factor for pneumonia in COPD 血糖控制不佳的糖尿病是慢性阻塞性肺病患者患肺炎的一个风险因素
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-07 DOI: 10.1016/j.resmer.2024.101135
Rafael Golpe , Juan-Marco Figueira-Gonçalves , Laura Arias-Zas , David Dacal-Rivas , Nagore Blanco-Cid , Olalla Castro-Añón

Background

Pneumonias are events of great prognostic significance in COPD, so it is important to identify predictive factors.

Objective

To determine whether poor glycemic control is related to an increased risk of pneumonia in COPD.

Method

A historical cohort study conducted in a COPD clinic. The first severe exacerbation after the first visit was analyzed. Exacerbations that presented with pulmonary infiltrates were identified. A Cox proportional hazards analysis was performed including the values of glycosylated hemoglobin (Hb1Ac) in patients with diabetes mellitus (DM) and variables that could plausibly be related to the risk of pneumonia. The best Hb1Ac value to predict pneumonia was assessed using receiver-operating characteristics analysis.

Results

There were 1124 cases included in the study. A total of 411 patients were admitted to the hospital at least once and 87 were diagnosed with pneumonia. Variables associated with the risk of pneumonia were previous admissions due to COPD and Hb1Ac values (HR: 2.33, 95% CI: 1.06 – 5.08, p = 0.03). A higher body mass index (BMI) was associated with a lower risk of pneumonia. The optimal cutoff point for Hb1Ac to predict pneumonia risk was 7.8 %. The patients were classified into 3 groups: (1) no DM, (2) controlled DM (Hb1AC < 7.8 %), (3) uncontrolled DM (Hb1AC ≥ 7.8 %). The risk of pneumonia for group 2 was not different from group 1, while the risk for group 3 was significantly higher than for groups 1 and 2 (HR: 4.52, 95 % CI: 1.57 – 13.02).

Conclusions

Poor control of DM is a predictor of the risk of pneumonia in COPD. The cutoff point of 7.8 % for this variable seems to be the most useful to identify patients at risk.

背景肺炎是慢性阻塞性肺疾病中对预后具有重要意义的事件,因此确定预测因素非常重要。目的确定血糖控制不佳是否与慢性阻塞性肺疾病肺炎风险增加有关。对首次就诊后的首次严重病情恶化进行分析。研究确定了出现肺部浸润的加重情况。对糖尿病(DM)患者的糖化血红蛋白(Hb1Ac)值以及可能与肺炎风险相关的变量进行了 Cox 比例危险度分析。研究采用受体运算特征分析法评估了预测肺炎的最佳 Hb1Ac 值。共有 411 名患者至少入院一次,其中 87 人被诊断为肺炎。与肺炎风险相关的变量是曾因慢性阻塞性肺病入院的患者和 Hb1Ac 值(HR:2.33,95% CI:1.06 - 5.08,p = 0.03)。体重指数(BMI)越高,患肺炎的风险越低。预测肺炎风险的最佳 Hb1Ac 临界点为 7.8%。患者分为三组:(1) 无糖尿病;(2) 已控制糖尿病(Hb1AC < 7.8 %);(3) 未控制糖尿病(Hb1AC ≥ 7.8 %)。结论DM控制不佳是慢性阻塞性肺病患者肺炎风险的预测因素。结论糖尿病控制不佳是慢性阻塞性肺病患者肺炎风险的预测因素,该变量的临界点为 7.8%,似乎最有助于识别高危患者。
{"title":"Diabetes mellitus with poor glycemic control is a risk factor for pneumonia in COPD","authors":"Rafael Golpe ,&nbsp;Juan-Marco Figueira-Gonçalves ,&nbsp;Laura Arias-Zas ,&nbsp;David Dacal-Rivas ,&nbsp;Nagore Blanco-Cid ,&nbsp;Olalla Castro-Añón","doi":"10.1016/j.resmer.2024.101135","DOIUrl":"10.1016/j.resmer.2024.101135","url":null,"abstract":"<div><h3>Background</h3><p>Pneumonias are events of great prognostic significance in COPD, so it is important to identify predictive factors.</p></div><div><h3>Objective</h3><p>To determine whether poor glycemic control is related to an increased risk of pneumonia in COPD.</p></div><div><h3>Method</h3><p>A historical cohort study conducted in a COPD clinic. The first severe exacerbation after the first visit was analyzed. Exacerbations that presented with pulmonary infiltrates were identified. A Cox proportional hazards analysis was performed including the values of glycosylated hemoglobin (Hb1Ac) in patients with diabetes mellitus (DM) and variables that could plausibly be related to the risk of pneumonia. The best Hb1Ac value to predict pneumonia was assessed using receiver-operating characteristics analysis.</p></div><div><h3>Results</h3><p>There were 1124 cases included in the study. A total of 411 patients were admitted to the hospital at least once and 87 were diagnosed with pneumonia. Variables associated with the risk of pneumonia were previous admissions due to COPD and Hb1Ac values (HR: 2.33, 95% CI: 1.06 – 5.08, <em>p</em> = 0.03). A higher body mass index (BMI) was associated with a lower risk of pneumonia. The optimal cutoff point for Hb1Ac to predict pneumonia risk was 7.8 %. The patients were classified into 3 groups: (1) no DM, (2) controlled DM (Hb1AC &lt; 7.8 %), (3) uncontrolled DM (Hb1AC ≥ 7.8 %). The risk of pneumonia for group 2 was not different from group 1, while the risk for group 3 was significantly higher than for groups 1 and 2 (HR: 4.52, 95 % CI: 1.57 – 13.02).</p></div><div><h3>Conclusions</h3><p>Poor control of DM is a predictor of the risk of pneumonia in COPD. The cutoff point of 7.8 % for this variable seems to be the most useful to identify patients at risk.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101135"},"PeriodicalIF":2.2,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sarcoidosis-like disease probably induced by apremilast: A case report 可能由阿普司特诱发的肉样瘤样疾病:病例报告
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-08-02 DOI: 10.1016/j.resmer.2024.101131
Paul Hannetel, Audrey Courdurie, Michael Levraut, Jacques Boutros, Alice Gaudart, Frederic Vandenbos
{"title":"Sarcoidosis-like disease probably induced by apremilast: A case report","authors":"Paul Hannetel,&nbsp;Audrey Courdurie,&nbsp;Michael Levraut,&nbsp;Jacques Boutros,&nbsp;Alice Gaudart,&nbsp;Frederic Vandenbos","doi":"10.1016/j.resmer.2024.101131","DOIUrl":"10.1016/j.resmer.2024.101131","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101131"},"PeriodicalIF":2.2,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142044618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of preexisting interstitial lung disease on outcomes of lung cancer surgery: A monocentric retrospective study 原有间质性肺病对肺癌手术结果的影响:单中心回顾性研究
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-30 DOI: 10.1016/j.resmer.2024.101126
Alice Goga , Alex Fourdrain , Paul Habert , Anh Thu Nguyen Ngoc , Julien Bermudez , Alice Mogenet , Eléonore Simon , Etienne Gouton , Pascale Tomasini , Pascal Alexandre Thomas , Laurent Greillier , Johan Pluvy

Introduction

Interstitial lung disease (ILD) is a known risk factor for lung cancer (LC). However, the surgical risk of LC in patients with ILD remains unclear. Therefore, we conducted a single-center retrospective study to assess clinical features and outcomes of LC population who underwent surgery with or without ILD.

Methods

Patients who underwent surgery for LC between January 2006 and June 2023 in our center were assessed using data extracted from the nationwide EPITHOR thoracic surgery database. Suspicion of ILD was based on patients’ records. Confirmation of ILD was then made on the patient's medical and radiological history. Patients were classified according to the pattern of ILD. The study aimed to describe the outcomes after lung cancer resection in patients with confirmed LC-ILD group compared to those without ILD (LC-non-ILD): post-operative complications, disease-free survival (DFS) and overall survival (OS). A subgroup analysis was also performed on patients with idiopathic pulmonary fibrosis and lung cancer (LC-IPF).

Results

4073 patients underwent surgery for LC at Assistance Publique des Hôpitaux de Marseille between January 2006 and June 2023. Of these, 4030 were in the LC-non-ILD group and 30 were LC-ILD patients. In the LC-ILD group, the predominant CT scan pattern was probable UIP (50 %). OS was not significantly lower in the LC-ILD group (45 months versus 84 months, p = 0.068). Dyspnea and tumor size were identified as potential univariate predictors of OS. No significant differences were observed on post-operative complications or their severity. The most common post-operative complications in the LC-ILD group were prolonged air leak, respiratory failure, or pneumonia. 13 patients had cancer recurrence in the LC-ILD group.

Conclusion

Our study provides a comprehensive analysis of a LC-ILD population features and outcome when undergoing surgery for LC. Patients with LC-ILD appeared to have a reduced OS compared with LC-non-ILD. Further investigations with larger prospective studies could be useful to confirm and develop these preliminary findings.

简介间质性肺病(ILD)是肺癌(LC)的已知危险因素。然而,ILD 患者的 LC 手术风险仍不明确。因此,我们进行了一项单中心回顾性研究,以评估接受手术的有或无 ILD 的 LC 患者的临床特征和预后:方法:使用从全国性 EPITHOR 胸外科数据库中提取的数据,对 2006 年 1 月至 2023 年 6 月期间在本中心接受 LC 手术的患者进行评估。根据患者的病历来怀疑是否存在 ILD。然后根据患者的病史和放射学病史确认是否患有 ILD。根据 ILD 的模式对患者进行分类。研究旨在描述确诊为LC-ILD组与未确诊为ILD组(LC-non-ILD)患者肺癌切除术后的结局:术后并发症、无病生存期(DFS)和总生存期(OS)。此外,还对特发性肺纤维化和肺癌(LC-IPF)患者进行了亚组分析:2006年1月至2023年6月期间,4073名患者在马赛公共医院援助中心接受了LC手术。其中,4030例为LC-非ILD组,30例为LC-ILD组。在LC-ILD组中,主要的CT扫描模式是可能的UIP(50%)。LC-ILD组的OS并没有明显降低(45个月对84个月,P = 0.068)。呼吸困难和肿瘤大小被认为是OS的潜在单变量预测因素。术后并发症及其严重程度无明显差异。LC-ILD 组最常见的术后并发症是长时间漏气、呼吸衰竭或肺炎。LC-ILD组有13名患者癌症复发:我们的研究全面分析了LC-ILD人群的特征以及接受LC手术的结果。与非LC-ILD患者相比,LC-ILD患者的OS似乎降低了。更大规模的前瞻性研究将有助于进一步证实和发展这些初步发现。
{"title":"Impact of preexisting interstitial lung disease on outcomes of lung cancer surgery: A monocentric retrospective study","authors":"Alice Goga ,&nbsp;Alex Fourdrain ,&nbsp;Paul Habert ,&nbsp;Anh Thu Nguyen Ngoc ,&nbsp;Julien Bermudez ,&nbsp;Alice Mogenet ,&nbsp;Eléonore Simon ,&nbsp;Etienne Gouton ,&nbsp;Pascale Tomasini ,&nbsp;Pascal Alexandre Thomas ,&nbsp;Laurent Greillier ,&nbsp;Johan Pluvy","doi":"10.1016/j.resmer.2024.101126","DOIUrl":"10.1016/j.resmer.2024.101126","url":null,"abstract":"<div><h3>Introduction</h3><p>Interstitial lung disease (ILD) is a known risk factor for lung cancer (LC). However, the surgical risk of LC in patients with ILD remains unclear. Therefore, we conducted a single-center retrospective study to assess clinical features and outcomes of LC population who underwent surgery with or without ILD.</p></div><div><h3>Methods</h3><p>Patients who underwent surgery for LC between January 2006 and June 2023 in our center were assessed using data extracted from the nationwide EPITHOR thoracic surgery database. Suspicion of ILD was based on patients’ records. Confirmation of ILD was then made on the patient's medical and radiological history. Patients were classified according to the pattern of ILD. The study aimed to describe the outcomes after lung cancer resection in patients with confirmed LC-ILD group compared to those without ILD (LC-non-ILD): post-operative complications, disease-free survival (DFS) and overall survival (OS). A subgroup analysis was also performed on patients with idiopathic pulmonary fibrosis and lung cancer (LC-IPF).</p></div><div><h3>Results</h3><p>4073 patients underwent surgery for LC at Assistance Publique des Hôpitaux de Marseille between January 2006 and June 2023. Of these, 4030 were in the LC-non-ILD group and 30 were LC-ILD patients. In the LC-ILD group, the predominant CT scan pattern was probable UIP (50 %). OS was not significantly lower in the LC-ILD group (45 months versus 84 months, <em>p</em> = 0.068). Dyspnea and tumor size were identified as potential univariate predictors of OS. No significant differences were observed on post-operative complications or their severity. The most common post-operative complications in the LC-ILD group were prolonged air leak, respiratory failure, or pneumonia. 13 patients had cancer recurrence in the LC-ILD group.</p></div><div><h3>Conclusion</h3><p>Our study provides a comprehensive analysis of a LC-ILD population features and outcome when undergoing surgery for LC. Patients with LC-ILD appeared to have a reduced OS compared with LC-non-ILD. Further investigation<del>s</del> with larger prospective studies could be useful to confirm and develop these preliminary findings.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101126"},"PeriodicalIF":2.2,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590041224000424/pdfft?md5=913718c8afc4cffa8ff0a0aea61d1b69&pid=1-s2.0-S2590041224000424-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An underrecognized phenotype of pulmonary emphysema with marked pulmonary gas exchange but with mild or moderate airway obstruction 一种未得到充分认识的肺气肿表型,具有明显的肺气体交换功能,但伴有轻度或中度气道阻塞。
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-27 DOI: 10.1016/j.resmer.2024.101086
Gaelle Weisenburger , Vincent Bunel , Cendrine Godet , Mathilde Salpin , Domitille Mouren , Charlotte Thibaut de Menonville , Tiphaine Goletto , Armelle Marceau , Raphael Borie , Marie-Pierre Debray , Hervé Mal

In patients with pulmonary emphysema and mild to moderate airflow limitation, one does not expect the features marked exertional dyspnea and hypoxemia as well as a profound decrease in diffusing capacity of the lung for carbon monoxide (DLCO). Here we describe this phenotype and its prognosis. From our database, we retrospectively selected cases associating emphysema, exertional breathlessness, O2 requirement at least upon exercise, forced expiratory volume in 1 sec (FEV1) ≥ 50% predicted, and DLCO ≤ 50% predicted, without associated combined pulmonary fibrosis and emphysema, right-to-left shunt, or severe pulmonary hypertension. Over a 12-year period, we identified 16 patients with emphysema and the above presentation. At the initial evaluation, the median age was 62 years (interquartile range 53.8–68.9). The median FEV1 and DLCO% predicted and mean pulmonary artery pressure were 86 (65–95)%, 38 (31–41)%, and 20 (17–25) mm Hg, respectively. On room air, the median arterial partial pressure of oxygen and partial pressure of carbon dioxide in arterial blood were 63.5 (55.8–69) mm Hg and 34.5 (31–36) mm Hg with increased median alveolar-arterial oxygen difference (46 [39–51] mm Hg). After the initial evaluation, the respiratory condition worsened in 13 of 14 (92.8%) patients with one or more re-evaluations (median follow-up 2.6 [0.9–5.8] years). In 12, lung transplantation was considered. Four patients died after 5.8, 5.7, 7.1, and 0.8 years of follow-up, respectively. We describe an underrecognized phenotype of pulmonary emphysema featuring a particular profile characterized by marked exertional dyspnea, impaired pulmonary gas exchange with low DLCO and marked oxygen desaturation at least on exercise but with mild or moderate airway obstruction.

对于肺气肿和轻度至中度气流受限的患者,人们不会想到他们会出现明显的劳力性呼吸困难和低氧血症,以及肺对一氧化碳的弥散能力(DLCO)的显著下降。在此,我们描述了这种表型及其预后。我们从数据库中回顾性地选择了肺气肿、劳累性呼吸困难、至少在运动时需要氧气、1 秒用力呼气容积(FEV1)≥ 预测值的 50%、DLCO ≤ 预测值的 50%,且没有合并肺纤维化和肺气肿、右向左分流或严重肺动脉高压的病例。在 12 年的时间里,我们发现了 16 名肺气肿患者,他们都有上述表现。初次评估时,患者的中位年龄为 62 岁(四分位数间距为 53.8-68.9)。预测 FEV1 和 DLCO% 的中位数以及平均肺动脉压分别为 86 (65-95)%、38 (31-41)% 和 20 (17-25) mm Hg。在室内空气中,动脉血氧分压和二氧化碳分压的中位数分别为 63.5(55.8-69)毫米汞柱和 34.5(31-36)毫米汞柱,肺泡-动脉血氧差的中位数增加(46 [39-51] 毫米汞柱)。初次评估后,14 名患者中有 13 人(92.8%)的呼吸状况恶化,需要进行一次或多次再评估(中位随访时间为 2.6 [0.9-5.8] 年)。其中 12 名患者考虑接受肺移植手术。四名患者分别在随访 5.8 年、5.7 年、7.1 年和 0.8 年后死亡。我们描述了一种未得到充分认识的肺气肿表型,其特点是明显的劳力性呼吸困难、肺气体交换受损(DLCO 较低)和明显的氧饱和度(至少在运动时),但伴有轻度或中度气道阻塞。
{"title":"An underrecognized phenotype of pulmonary emphysema with marked pulmonary gas exchange but with mild or moderate airway obstruction","authors":"Gaelle Weisenburger ,&nbsp;Vincent Bunel ,&nbsp;Cendrine Godet ,&nbsp;Mathilde Salpin ,&nbsp;Domitille Mouren ,&nbsp;Charlotte Thibaut de Menonville ,&nbsp;Tiphaine Goletto ,&nbsp;Armelle Marceau ,&nbsp;Raphael Borie ,&nbsp;Marie-Pierre Debray ,&nbsp;Hervé Mal","doi":"10.1016/j.resmer.2024.101086","DOIUrl":"10.1016/j.resmer.2024.101086","url":null,"abstract":"<div><p>In patients with pulmonary emphysema and mild to moderate airflow limitation, one does not expect the features marked exertional dyspnea and hypoxemia as well as a profound decrease in diffusing capacity of the lung for carbon monoxide (DLCO). Here we describe this phenotype and its prognosis. From our database, we retrospectively selected cases associating emphysema, exertional breathlessness, O<sub>2</sub> requirement at least upon exercise, forced expiratory volume in 1 sec (FEV<sub>1</sub>) ≥ 50% predicted, and DLCO ≤ 50% predicted, without associated combined pulmonary fibrosis and emphysema, right-to-left shunt, or severe pulmonary hypertension<del>.</del> Over a 12-year period, we identified 16 patients with emphysema and the above presentation. At the initial evaluation, the median age was 62 years (interquartile range 53.8–68.9). The median FEV<sub>1</sub> and DLCO% predicted and mean pulmonary artery pressure were 86 (65–95)%, 38 (31–41)%, and 20 (17–25) mm Hg, respectively. On room air, the median arterial partial pressure of oxygen and partial pressure of carbon dioxide in arterial blood were 63.5 (55.8–69) mm Hg and 34.5 (31–36) mm Hg with increased median alveolar-arterial oxygen difference (46 [39–51] mm Hg). After the initial evaluation, the respiratory condition worsened in 13 of 14 (92.8%) patients with one or more re-evaluations (median follow-up 2.6 [0.9–5.8] years). In 12, lung transplantation was considered. Four patients died after 5.8, 5.7, 7.1, and 0.8 years of follow-up, respectively. We describe an underrecognized phenotype of pulmonary emphysema featuring a particular profile characterized by marked exertional dyspnea, impaired pulmonary gas exchange with low DLCO and marked oxygen desaturation at least on exercise but with mild or moderate airway obstruction.</p></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101086"},"PeriodicalIF":2.2,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141789541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Particle size distribution of viable nebulized bacteriophage for the treatment of multi-drug resistant Pseudomonas aeruginosa 用于治疗多重耐药铜绿假单胞菌的可行雾化噬菌体的粒度分布
IF 2.2 4区 医学 Q3 RESPIRATORY SYSTEM Pub Date : 2024-07-25 DOI: 10.1016/j.resmer.2024.101133
Daniel L Thompson , Zoe Semersky , Richard Feinn , Pamela Huang , Paul E Turner , Ben K Chan , Jonathan L Koff , Thomas S Murray
{"title":"Particle size distribution of viable nebulized bacteriophage for the treatment of multi-drug resistant Pseudomonas aeruginosa","authors":"Daniel L Thompson ,&nbsp;Zoe Semersky ,&nbsp;Richard Feinn ,&nbsp;Pamela Huang ,&nbsp;Paul E Turner ,&nbsp;Ben K Chan ,&nbsp;Jonathan L Koff ,&nbsp;Thomas S Murray","doi":"10.1016/j.resmer.2024.101133","DOIUrl":"10.1016/j.resmer.2024.101133","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"86 ","pages":"Article 101133"},"PeriodicalIF":2.2,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141849189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Respiratory Medicine and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1